Cilansetron

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Cilansetron
Cilansetron.svg
Clinical data
SynonymsCalmactin; KC 9946
Pregnancy
category
  • C
Routes of
administration
Oral
ATC code
Legal status
Legal status
  • Unlicensed
Pharmacokinetic data
Bioavailability87%
MetabolismHepatic
Elimination half-life1.6 - 1.9 hours
ExcretionRenal
Identifiers
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC20H21N3O
Molar mass319.408 g·mol−1
3D model (JSmol)
  (verify)

Cilansetron is an experimental drug that is a 5-HT3 antagonist under development by Solvay Pharmaceuticals.

5-HT3 receptors are responsible for causing many things from nausea to excess bowel movements. In conditions such as irritable bowel syndrome (IBS), the receptors have become faulty or oversensitive. 5-HT3 antagonists work by blocking the nervous and chemical signals from reaching these receptors.

Studies have shown that the drug can improve quality of life in men and women with diarrhea-predominant IBS.[1] Cilansetron is the first 5-HT antagonist specifically designed for IBS that is effective in men as well as women.[1]

In 2005, Solvay received response from the U.S. Food and Drug Administration that cilanserton is not approvable without additional clinical trials;[2][3] further development has been discontinued.[4]

References[edit]

  1. ^ a b General info on Cilansetron
  2. ^ "Solvay's cilansetron "not approvable"". PharmaTimes. April 4, 2005. Retrieved August 14, 2019.
  3. ^ "Calmactin Approval Status". Drugs.com. Retrieved August 14, 2019.
  4. ^ "Cilansetron". Retrieved August 14, 2019.